# Jose Lutzky

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jose-lutzky/

## Facts

| Field | Value |
| --- | --- |
| Citations | 25,917 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 48 |
| i10-index | 94 |
| Last Known Institution | University of Miami |
| OpenAlex ID | https://openalex.org/A5044615683 |
| ORCID iD | https://orcid.org/0000-0002-9503-2130 |
| Works | 215 |

## Researcher papers

- [Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial](https://scholariq.org/papers/pembrolizumab-plus-pomalidomide-and-dexamethasone-for-patients-with-relapsed-or/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)

## Researcher university

- [University of Miami](https://scholariq.org/institutions/university-of-miami/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.